Bellerophon Therapeutics Stock EBITDA

BLPHDelisted Stock  USD 0.71  0.01  1.43%   
Bellerophon Therapeutics fundamentals help investors to digest information that contributes to Bellerophon Therapeutics' financial success or failures. It also enables traders to predict the movement of Bellerophon Pink Sheet. The fundamental analysis module provides a way to measure Bellerophon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellerophon Therapeutics pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bellerophon Therapeutics Company EBITDA Analysis

Bellerophon Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Bellerophon Therapeutics EBITDA

    
  (22.39 M)  
Most of Bellerophon Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellerophon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Bellerophon Therapeutics reported earnings before interest,tax, depreciation and amortization of (22.39 Million). This is 102.55% lower than that of the Health Care Equipment & Supplies sector and 122.35% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.57% higher than that of the company.

Bellerophon EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellerophon Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellerophon Therapeutics could also be used in its relative valuation, which is a method of valuing Bellerophon Therapeutics by comparing valuation metrics of similar companies.
Bellerophon Therapeutics is currently under evaluation in ebitda category among its peers.

Bellerophon Fundamentals

About Bellerophon Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bellerophon Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellerophon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellerophon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Bellerophon Pink Sheet

If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk